Calling a compound a melanocortin receptor agonist names a family, not a target. There are five of these receptors, spread across different tissues, and a molecule that reaches one will usually touch some of the others. Which ones, and how strongly, is the question that most work on these compounds is built around.

Five receptors, cloned in a burst

The family is labelled MC1R through MC5R. The first members were cloned in 1992, and the rest followed quickly, which is why so much of the foundational literature clusters in a few years. (Reference: Mountjoy et al., 1992) They are G protein-coupled receptors, and they are among the smaller ones: the extracellular portions that many receptors use to grip a large ligand are short here. Recognition happens mostly within the membrane-spanning bundle, which sets a limit on how much of a ligand the receptor can read.

Their distribution across tissues differs, and that distribution is most of what separates them functionally. A receptor only acts where it is expressed.

One precursor, several signals

The natural ligands for these receptors come from a single precursor protein, proopiomelanocortin, which is cut into several smaller peptides. One gene therefore yields several distinct signalling molecules, and which ones appear depends on how the precursor is processed in a given tissue. (Reference: Cone, 2006)

Those fragments overlap in sequence, and several of them bind more than one receptor subtype. The system was built with cross-talk in it, which is why selectivity is difficult to achieve and interesting to measure.

A family with natural antagonists

Most receptor systems are studied with agonists that occur in nature and antagonists that chemists build. The melanocortin family has endogenous antagonists as well: proteins that bind these receptors and block them instead of switching them on. (Reference: Cone, 2006)

The existence of a natural blocker matters when reading results, because the baseline state of the receptor in a tissue is set by the balance between two opposing signals. Our note on agonists and antagonists covers the vocabulary, including why a receptor can carry activity with nothing bound to it at all.

What the subtypes are associated with

The subtypes are linked to different processes. MC1R is the one associated with pigmentation, which is where the family name comes from. Others are tied to central signalling in the nervous system, and others to peripheral tissues. (Reference: Cone, 2006)

The honest summary is that a compound described as acting on melanocortin receptors has not been described precisely. The subtype, and how cleanly it is reached, is the information that matters.

Why selectivity is hard here

Receptors in one family share the regions that recognise a ligand, and the melanocortin family shares them closely. A peptide shaped to fit one subtype fits its relatives to some degree, so selectivity is measured as a ratio rather than claimed as an absolute: this subtype over that one, by some factor, under stated conditions.

One route around the problem is to constrain the peptide's shape. Cyclic analogues, in which a bridge between two side chains locks the backbone, were developed for this family in the 1980s and proved considerably more potent than their flexible counterparts. (Reference: Al-Obeidi et al., 1989) PT-141 belongs to that structural lineage, and our note on cyclic and linear peptides covers what the constraint does.

The shared core of the ligands

The melanocortin peptides overlap in a short stretch of sequence that carries most of the receptor recognition. A handful of residues in that stretch does the essential work, which is why very short synthetic analogues can still activate these receptors while much longer fragments of the precursor are not needed. (Reference: Cone, 2006)

That compact recognition motif is convenient for a chemist and inconvenient for selectivity. A small set of residues gives fewer positions to vary, so the differences that distinguish one subtype from another have to be found within a narrow space. It is also why constraining the backbone, rather than lengthening the sequence, became the main design strategy for this family.

What a receptor number does not tell you

Subtype labels are useful shorthand and easy to over-read. MC1R and MC4R are different proteins with different distributions, but a compound that reaches one at a given concentration may reach the other at a concentration only a few times higher. A selectivity of tenfold and a selectivity of a thousandfold are both reported as selective, and only one of them supports attributing an observation to a single subtype.

Reading a claim about selectivity

A selectivity figure is a comparison produced by an assay, so it carries the assay's assumptions with it. How many receptors were present, which downstream event was measured, and which subtypes were included in the comparison all shape the number. Two papers can report different selectivity for the same compound without either being wrong. The number belongs to the experiment as much as to the molecule.

The same caution applies to the word potent. Potency and selectivity are separate measurements, and a compound can be strong at a receptor while being poor at telling that receptor apart from its neighbours.

What none of this tells you about a vial

Receptor pharmacology describes a molecule. It says nothing about the material in front of you: whether this batch contains that molecule, and how much of it does. Those come from a purity measurement by HPLC and an identity measurement by mass spectrometry, reported on a certificate of analysis bearing the batch number on your label, which you can look up.

Research use only

This article is background pharmacology for laboratory context. All products sold by Codex Research are strictly for research and development, are not for human or animal consumption, and are not intended to diagnose, treat, cure, or prevent any disease.

These compounds in the catalog

Frequently asked questions

What are melanocortin receptors?

A family of five G protein-coupled receptors, labelled MC1R through MC5R, distributed across different tissues. The first members were cloned in 1992. They respond to peptides derived from a single precursor protein.

Where do the natural ligands come from?

From one precursor protein, proopiomelanocortin, which is cut into several smaller peptides. A single gene therefore yields several signalling molecules, and which ones appear depends on how the precursor is processed in a given tissue.

Does this family have natural antagonists?

Yes, which is unusual. Proteins exist that bind these receptors and block them instead of activating them, so the baseline state of a receptor in a tissue reflects the balance between two opposing signals.

Why is subtype selectivity difficult for melanocortin compounds?

Because the receptors in the family share the regions that recognise a ligand. A peptide shaped to fit one subtype fits its relatives to some degree, so selectivity is reported as a ratio between subtypes under stated conditions, not as an absolute.

How do cyclic analogues fit in?

Constraining a peptide into a ring with a bridge between two side chains narrows the shapes it can adopt. Cyclic analogues developed for this family in the 1980s proved considerably more potent than flexible ones, and later melanocortin peptides belong to that lineage.

Can two papers report different selectivity for the same compound?

Yes. A selectivity figure comes from an assay and carries its assumptions: how many receptors were present, which downstream event was measured, and which subtypes were compared. Different systems can give different numbers without either being wrong.

References

Related articles